Opioid Dose Escalation Patterns in Chronic Kidney Disease Patients

Encompassing results from a cohort study of 81,987 adult new opioid users in Sweden from 2012 to 2021, analyzing dose escalation patterns across kidney function levels. It includes findings on the proportion of patients escalating to ≥50 and ≥90 MME/day, with hazard ratios from competing-risks regression.

Use Cases

• Analyze the proportion of patients escalating to ≥50 MME/day across eGFR categories (≥60, 30–59, <30 mL/min/1.73m²).
• Model time to dose escalation (≥90 MME/day) using Fine-Gray competing-risks regression, accounting for death as a competing event.
• Investigate the sub distribution hazard ratios (SHRs) for dose escalation among patients with reduced eGFR levels.
• Examine the timing of opioid dose escalation, which the study found mostly occurred within six months.

Strengths

• Based on a population-based cohort of 81,987 adult new opioid users.
• Covers a 10-year time range from 2012 to 2021.
• Provides specific hazard ratios and confidence intervals for dose escalation risks across eGFR levels.

Limitations

• The dataset is very small at 9.5 KB, suggesting it contains summary results rather than patient-level records.
• No column or sample data is provided, limiting understanding of the raw data structure.
• The data is specific to the Stockholm region (Sweden), which may limit generalizability.

Provenance

Source

Stockholm Creatinine Measurements (SCREAM) project.

Collection Method

Population-based cohort study linking diagnoses, prescriptions, and laboratory records.

Time Range

2012 to 2021.

Freshness

Last updated March 20, 2026.

Geography

Stockholm, Sweden.